Xuan Sun
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Xuan Sun has a total of 112 co-authors. Here are the top co-authors by number of shared publications:
- Zhongrong Miao
Capital Medical University
8 shared publications - Dapeng Mo
Department of Interventional Neuroradiology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
5 shared publications - Ning Ma
Department of Interventional Neuroradiology, Beijing Tiantan Hospital Capital Medical University Beijing China
5 shared publications - Yilong Wang
Capital Medical University
5 shared publications - Dapeng Sun
Capital Medical University
4 shared publications - Feng Gao
Interventional Neuroradiology, Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
4 shared publications
Latest Publications
- 12 November 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
Sex‐Stratified Outcomes in Balloon Angioplasty for Symptomatic Intracranial Artery Stenosis: The BASIS Subgroup Analysis
Background: The BASIS (Balloon Angioplasty for Symptomatic Intracranial Artery Stenosis) trial demonstrated that balloon angioplasty plus aggressive medical management was superior to aggressive medical management alone for symptomatic intracranial atherosclerotic stenosis. However, whether sex modifies this treatment effect is unknown. Methods: This prespecified secondary analysis of the BASIS randomized controlled trial included 501 patients with symptomatic intracranial atherosclerotic stenosis from 31 Chinese centers (November 2018 to April 2022). Baseline characteristics and outcomes were compared between sexes and across treatment arms within each sex. The primary outcome was stroke or death within 30 days, or ischemic stroke in the qualifying artery territory or revascularization beyond 30 days through 12 months. Results: Among 501 patients (mean age, 58 years), 158 (31.5%) were women. No significant sex‐by‐treatment interaction was observed for primary or key secondary outcomes (all P for interaction >0.05). In sex‐stratified analyses, balloon angioplasty reduced primary outcome risk versus aggressive medical management in men (2.9% versus 11.1%; hazard ratio [HR]=0.21 [95% CI, 0.07–0.65]; P =0.01). In women, the effect favored balloon angioplasty but was not statistically significant (7.8% versus 18.5%; HR=0.37 [95% CI, 0.14–1.01]; P =0.051). Conclusions: No significant interaction between sex and treatment effect was found, suggesting balloon angioplasty's benefit relative to aggressive medical management does not clearly differ by sex. Sex‐stratified results showed significant benefit in men and a nonsignificant trend in women, but the study lacked power for definitive interaction testing, so findings are exploratory. Further research is needed to confirm these findings in broader populations. Registration: URL: https://www.clinicaltrials.gov ; Unique Identifier: NCT03703635.
- 12 November 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
Sex‐Stratified Outcomes in Balloon Angioplasty for Symptomatic Intracranial Artery Stenosis: The BASIS Subgroup Analysis
Background: The BASIS (Balloon Angioplasty for Symptomatic Intracranial Artery Stenosis) trial demonstrated that balloon angioplasty plus aggressive medical management was superior to aggressive medical management alone for symptomatic intracranial atherosclerotic stenosis. However, whether sex modifies this treatment effect is unknown. Methods: This prespecified secondary analysis of the BASIS randomized controlled trial included 501 patients with symptomatic intracranial atherosclerotic stenosis from 31 Chinese centers (November 2018 to April 2022). Baseline characteristics and outcomes were compared between sexes and across treatment arms within each sex. The primary outcome was stroke or death within 30 days, or ischemic stroke in the qualifying artery territory or revascularization beyond 30 days through 12 months. Results: Among 501 patients (mean age, 58 years), 158 (31.5%) were women. No significant sex‐by‐treatment interaction was observed for primary or key secondary outcomes (all P for interaction >0.05). In sex‐stratified analyses, balloon angioplasty reduced primary outcome risk versus aggressive medical management in men (2.9% versus 11.1%; hazard ratio [HR]=0.21 [95% CI, 0.07–0.65]; P =0.01). In women, the effect favored balloon angioplasty but was not statistically significant (7.8% versus 18.5%; HR=0.37 [95% CI, 0.14–1.01]; P =0.051). Conclusions: No significant interaction between sex and treatment effect was found, suggesting balloon angioplasty's benefit relative to aggressive medical management does not clearly differ by sex. Sex‐stratified results showed significant benefit in men and a nonsignificant trend in women, but the study lacked power for definitive interaction testing, so findings are exploratory. Further research is needed to confirm these findings in broader populations. Registration: URL: https://www.clinicaltrials.gov ; Unique Identifier: NCT03703635.
- 1 September 2026
- Published by Wolters Kluwer Health in Stroke
- Vol. 57 (9)
Balloon Angioplasty by Prior Stroke History in Intracranial Artery Stenosis: A Post Hoc Analysis of the BASIS Trial
- 1 September 2026
- Published by Wolters Kluwer Health in Stroke
- Vol. 57 (9)
Balloon Angioplasty by Prior Stroke History in Intracranial Artery Stenosis: A Post Hoc Analysis of the BASIS Trial
- 1 January 2026
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 318 (1) , e250893
Drug-coated Balloon for Endovascular Treatment of Symptomatic Intracranial Stenotic Disease: A Multicenter Randomized Controlled Trial
Drug-coated balloon angioplasty showed lower restenosis and ischemic event rates than bare-metal stent placement in symptomatic high-grade intracranial stenosis, with comparable safety.
- 1 January 2026
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 318 (1) , e250893
Drug-coated Balloon for Endovascular Treatment of Symptomatic Intracranial Stenotic Disease: A Multicenter Randomized Controlled Trial
Drug-coated balloon angioplasty showed lower restenosis and ischemic event rates than bare-metal stent placement in symptomatic high-grade intracranial stenosis, with comparable safety.
- Open Access
- 31 October 2025
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 16, 1623245
Impact of smoking status and smoking index on outcomes in patients with acute basilar artery occlusion
Purpose: This study aims to investigate the relationship between smoking status, smoking index, and the outcomes of intravascular treatment for acute basilar artery occlusion within 24 h. Methods: We retrospectively analyzed all consecutive patients hospitalized with acute basilar artery occlusion who underwent endovascular treatment within 24 h from January 2012 to July 2018 at Beijing Tiantan Hospital. Smoking status was categorized as never smoking, current smoking, or previous smoking. The smoking index (SI) was calculated as the daily smoking count multiplied by the number of smoking years. The primary outcomes were a 90-day modified Rankin Scale score shift analysis and mortality at 90 days. Results: The overall study cohort comprised 59 never smokers, 58 former smokers, and 70 current smokers. No significant differences in primary outcomes were observed between smoking status and functional independence (OR, 1.611; 95% CI, 0.776–3.344) or death (OR, 0.461; 95% CI, 0.196–1.084). Multivariate analysis indicated that smoking status had limited relevance to functional independence (OR, 1.958; 95% CI, 0.781–4.907) and death (OR, 0.446; 95% CI, 0.169–1.178). The smoking index was independently associated with functional independence (OR, 1.095; 95% CI, 1.015–1.182) and death (OR, 0.844; 95% CI, 0.757–0.941). The smoking index demonstrated a dose–effect relationship with outcomes, being positively correlated with functional independence and negatively correlated with death. Conclusion: Smoking status does not appear to influence prognosis. However, the smoking index may be associated with improved functional independence and a reduced risk of death, demonstrating a dose-effect relationship.
- 31 October 2025
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 16, 1623245
Open AccessImpact of smoking status and smoking index on outcomes in patients with acute basilar artery occlusion
Purpose: This study aims to investigate the relationship between smoking status, smoking index, and the outcomes of intravascular treatment for acute basilar artery occlusion within 24 h. Methods: We retrospectively analyzed all consecutive patients hospitalized with acute basilar artery occlusion who underwent endovascular treatment within 24 h from January 2012 to July 2018 at Beijing Tiantan Hospital. Smoking status was categorized as never smoking, current smoking, or previous smoking. The smoking index (SI) was calculated as the daily smoking count multiplied by the number of smoking years. The primary outcomes were a 90-day modified Rankin Scale score shift analysis and mortality at 90 days. Results: The overall study cohort comprised 59 never smokers, 58 former smokers, and 70 current smokers. No significant differences in primary outcomes were observed between smoking status and functional independence (OR, 1.611; 95% CI, 0.776–3.344) or death (OR, 0.461; 95% CI, 0.196–1.084). Multivariate analysis indicated that smoking status had limited relevance to functional independence (OR, 1.958; 95% CI, 0.781–4.907) and death (OR, 0.446; 95% CI, 0.169–1.178). The smoking index was independently associated with functional independence (OR, 1.095; 95% CI, 1.015–1.182) and death (OR, 0.844; 95% CI, 0.757–0.941). The smoking index demonstrated a dose–effect relationship with outcomes, being positively correlated with functional independence and negatively correlated with death. Conclusion: Smoking status does not appear to influence prognosis. However, the smoking index may be associated with improved functional independence and a reduced risk of death, demonstrating a dose-effect relationship.
- Open Access
- 28 October 2025
- Published by BMJ in Stroke and Vascular Neurology
- Vol. 11 (3) , 381-388
Contact aspiration versus stent retriever thrombectomy for acute basilar artery occlusion (ANGEL-COAST): rationale and design of a multicentre, prospective, randomised, open-label, blinded-endpoint trial
Background: Contact aspiration (CA) and stent retriever (SR) thrombectomy are two equally recommended first-line endovascular techniques for treating acute ischaemic stroke due to large vessel occlusion. Whether CA is more effective in achieving complete reperfusion compared with SR in patients with acute basilar artery occlusion (ABAO) remains unclear. Aim: This study aims to compare the efficacy and safety of CA versus SR as the first-line strategy during endovascular treatment in improving the rates of first-pass effect (FPE) for patients with ABAO. Methods and design: The ANGEL-COAST study is a prospective, multicentre, randomised controlled, open-label, blinded-endpoint (PROBE) clinical trial. Patients with acute ischaemic stroke due to ABAO within 24 hours from symptom onset will be recruited. Participants will be randomly assigned in a 1:1 ratio to either the CA or SR group. If the assigned treatment fails after three attempts, investigators may opt for alternative treatment strategies based on their clinical judgement. Study outcomes: The primary endpoint is the FPE rate, defined as eTICI (Extended Thrombolysis in Cerebral Infarction) 2C/3 recanalisation after the first thrombectomy attempt without any rescue strategy. Key secondary endpoints include rates of modified FPE (eTICI ≥2b50), successful recanalisation (eTICI ≥2b50, eTICI ≥2b67, eTICI3) within ≤3 passes with the assigned device on conclusion of the procedure, procedural duration, use of rescue techniques and functional outcomes at 90 days, including modified Rankin Scale (mRS) 0–2 and mRS ordinal shift analysis. Safety outcomes include the rates of symptomatic intracerebral haemorrhage (sICH) at 36±12 hours, all-cause 90-day mortality and procedure-related serious adverse events. Discussion: This is a head-to-head randomised trial to directly compare CA and SR in ABAO. The findings will help establish the optimal first-line endovascular treatment strategy for ABAO, potentially improving clinical outcomes in this high-risk group. Trial registration number: https://www.clinicaltrials.gov ; Unique identifier: NCT05615038 .
- 28 October 2025
- Published by BMJ in Stroke and Vascular Neurology
- Vol. 11 (3) , 381-388
Open AccessContact aspiration versus stent retriever thrombectomy for acute basilar artery occlusion (ANGEL-COAST): rationale and design of a multicentre, prospective, randomised, open-label, blinded-endpoint trial
Background: Contact aspiration (CA) and stent retriever (SR) thrombectomy are two equally recommended first-line endovascular techniques for treating acute ischaemic stroke due to large vessel occlusion. Whether CA is more effective in achieving complete reperfusion compared with SR in patients with acute basilar artery occlusion (ABAO) remains unclear. Aim: This study aims to compare the efficacy and safety of CA versus SR as the first-line strategy during endovascular treatment in improving the rates of first-pass effect (FPE) for patients with ABAO. Methods and design: The ANGEL-COAST study is a prospective, multicentre, randomised controlled, open-label, blinded-endpoint (PROBE) clinical trial. Patients with acute ischaemic stroke due to ABAO within 24 hours from symptom onset will be recruited. Participants will be randomly assigned in a 1:1 ratio to either the CA or SR group. If the assigned treatment fails after three attempts, investigators may opt for alternative treatment strategies based on their clinical judgement. Study outcomes: The primary endpoint is the FPE rate, defined as eTICI (Extended Thrombolysis in Cerebral Infarction) 2C/3 recanalisation after the first thrombectomy attempt without any rescue strategy. Key secondary endpoints include rates of modified FPE (eTICI ≥2b50), successful recanalisation (eTICI ≥2b50, eTICI ≥2b67, eTICI3) within ≤3 passes with the assigned device on conclusion of the procedure, procedural duration, use of rescue techniques and functional outcomes at 90 days, including modified Rankin Scale (mRS) 0–2 and mRS ordinal shift analysis. Safety outcomes include the rates of symptomatic intracerebral haemorrhage (sICH) at 36±12 hours, all-cause 90-day mortality and procedure-related serious adverse events. Discussion: This is a head-to-head randomised trial to directly compare CA and SR in ABAO. The findings will help establish the optimal first-line endovascular treatment strategy for ABAO, potentially improving clinical outcomes in this high-risk group. Trial registration number: https://www.clinicaltrials.gov ; Unique identifier: NCT05615038 .
- 12 August 2025
- Published by Elsevier in Plant Science
- Vol. 360, 112720
DPE1, a novel allelic of BT1, is critical for maize endosperm development and carbohydrate metabolism
- 12 August 2025
- Published by Elsevier in Plant Science
- Vol. 360, 112720
DPE1, a novel allelic of BT1, is critical for maize endosperm development and carbohydrate metabolism
- 8 May 2025
- Published by BMJ in Journal of NeuroInterventional Surgery
- Vol. 18 (4) , 1010-1016
A Multicenter retrospective study of the COSIS technique in the treatment of chronic internal carotid artery occlusion
Objective Our study aims to introduce a novel interventional treatment strategy for the management of chronic occlusion of the internal carotid artery (CO-ICA) using a specially designed thrombectomy stent, named the Chronic artery OccluSion recanalization with Intracranial protection using Stent retriever (COSIS) technique. Methods Thirty-two patients from four centers with CO-ICA between March 2023 to September 2024 were analyzed, retrospectively. All patients were classified into four types based on the occlusion segment. Patient demographics, endovascular thrombectomy (EVT) details, recanalization rates, intraoperative complications, and follow-up outcomes were evaluated. Results All 32 patients achieved successful recanalization. Dissection occurred in four patients (12.50%). No reocclusion, perforation, or other severe intraoperative complications occurred. Thrombus was extracted in 21 patients (65.62%). The median modified Rankin Scale (mRS) score at the 3 month follow-up was 1.0 (interquartile range (IQR): 0.0–1.0). The recanalization success rate and intraoperative complications showed no significant differences among the four types of occlusions. Conclusion The COSIS technique has improved the recanalization rate and safety in different types of CO-ICA patients. Further prospective studies are needed to validate its clinical efficacy.
- 8 May 2025
- Published by BMJ in Journal of NeuroInterventional Surgery
- Vol. 18 (4) , 1010-1016
A Multicenter retrospective study of the COSIS technique in the treatment of chronic internal carotid artery occlusion
Objective Our study aims to introduce a novel interventional treatment strategy for the management of chronic occlusion of the internal carotid artery (CO-ICA) using a specially designed thrombectomy stent, named the Chronic artery OccluSion recanalization with Intracranial protection using Stent retriever (COSIS) technique. Methods Thirty-two patients from four centers with CO-ICA between March 2023 to September 2024 were analyzed, retrospectively. All patients were classified into four types based on the occlusion segment. Patient demographics, endovascular thrombectomy (EVT) details, recanalization rates, intraoperative complications, and follow-up outcomes were evaluated. Results All 32 patients achieved successful recanalization. Dissection occurred in four patients (12.50%). No reocclusion, perforation, or other severe intraoperative complications occurred. Thrombus was extracted in 21 patients (65.62%). The median modified Rankin Scale (mRS) score at the 3 month follow-up was 1.0 (interquartile range (IQR): 0.0–1.0). The recanalization success rate and intraoperative complications showed no significant differences among the four types of occlusions. Conclusion The COSIS technique has improved the recanalization rate and safety in different types of CO-ICA patients. Further prospective studies are needed to validate its clinical efficacy.
- Open Access
- 18 May 2023
- Published by BMJ in Stroke and Vascular Neurology
- Vol. 9 (1) , 66-74
Balloon Angioplasty for Symptomatic Intracranial Artery Stenosis (BASIS): protocol of a prospective, multicentre, randomised, controlled trial
Background The superiority of balloon angioplasty plus aggressive medical management (AMM) to AMM alone for symptomatic intracranial artery stenosis (sICAS) on efficacy and safety profiles still lacks evidence from randomised controlled trials (RCTs). Aim To demonstrate the design of an RCT on balloon angioplasty plus AMM for sICAS. Design Balloon Angioplasty for Symptomatic Intracranial Artery Stenosis (BASIS) trial is a multicentre, prospective, randomised, open-label, blinded end-point trial to investigate whether balloon angioplasty plus AMM could improve clinical outcome compared with AMM alone in patients with sICAS. Patients eligible in BASIS were 35–80 years old, with a recent transient ischaemic attack within the past 90 days or ischaemic stroke between 14 days and 90 days prior to enrolment due to severe atherosclerotic stenosis (70%–99%) of a major intracranial artery. The eligible patients were randomly assigned to receive balloon angioplasty plus AMM or AMM alone at a 1:1 ratio. Both groups will receive identical AMM, including standard dual antiplatelet therapy for 90 days followed by long-term single antiplatelet therapy, intensive risk factor management and life-style modification. All participants will be followed up for 3 years. Study outcomes Stroke or death in the next 30 days after enrolment or after balloon angioplasty procedure of the qualifying lesion during follow-up, or any ischaemic stroke or revascularisation from the qualifying artery after 30 days but before 12 months of enrolment, is the primary outcome. Discussion BASIS trail is the first RCT to compare the efficacy and safety of balloon angioplasty plus AMM to AMM alone in sICAS patients, which may provide an alternative perspective for treating sICAS. Trial registration number NCT03703635; https://www.clinicaltrials.gov.
- 18 May 2023
- Published by BMJ in Stroke and Vascular Neurology
- Vol. 9 (1) , 66-74
Open AccessBalloon Angioplasty for Symptomatic Intracranial Artery Stenosis (BASIS): protocol of a prospective, multicentre, randomised, controlled trial
Background The superiority of balloon angioplasty plus aggressive medical management (AMM) to AMM alone for symptomatic intracranial artery stenosis (sICAS) on efficacy and safety profiles still lacks evidence from randomised controlled trials (RCTs). Aim To demonstrate the design of an RCT on balloon angioplasty plus AMM for sICAS. Design Balloon Angioplasty for Symptomatic Intracranial Artery Stenosis (BASIS) trial is a multicentre, prospective, randomised, open-label, blinded end-point trial to investigate whether balloon angioplasty plus AMM could improve clinical outcome compared with AMM alone in patients with sICAS. Patients eligible in BASIS were 35–80 years old, with a recent transient ischaemic attack within the past 90 days or ischaemic stroke between 14 days and 90 days prior to enrolment due to severe atherosclerotic stenosis (70%–99%) of a major intracranial artery. The eligible patients were randomly assigned to receive balloon angioplasty plus AMM or AMM alone at a 1:1 ratio. Both groups will receive identical AMM, including standard dual antiplatelet therapy for 90 days followed by long-term single antiplatelet therapy, intensive risk factor management and life-style modification. All participants will be followed up for 3 years. Study outcomes Stroke or death in the next 30 days after enrolment or after balloon angioplasty procedure of the qualifying lesion during follow-up, or any ischaemic stroke or revascularisation from the qualifying artery after 30 days but before 12 months of enrolment, is the primary outcome. Discussion BASIS trail is the first RCT to compare the efficacy and safety of balloon angioplasty plus AMM to AMM alone in sICAS patients, which may provide an alternative perspective for treating sICAS. Trial registration number NCT03703635; https://www.clinicaltrials.gov.
- 1 May 2023
- Published by Wolters Kluwer Health in Stroke
- Vol. 54 (5) , 1377-1389
TRIM29 (Tripartite Motif Containing 29) Alleviates NLRC4 (NLR Family CARD Domain Containing Protein 4) Inflammasome Related Cerebral Injury via Promoting Proteasomal Degradation of NLRC4 in Ischemic Stroke
Background: Neuroinflammation plays extremely crucial roles in the neurological damage mediated by ischemic stroke. TRIM29 (tripartite motif containing 29) has previously been proposed to contribute to the regulation of innate immunity, however, the effect of TRIM29 on ischemic stroke induced neurodegenerative processes and neuroinflammation still largely unexplored. In the current article, we aimed to investigate the function and the precise mechanisms of TRIM29 in ischemic stroke. Methods: Middle cerebral artery occlusion mice model and oxygen-glucose deprivation cell model were established as in vivo and in vitro models of ischemic stroke. Quantitative real-time polymerase chain reaction (PCR), Western blot, and ELSIA were used to detect the expression levels of TRIM29, cytokines, and marker proteins. Immunofluorescence assay was performed to examine the extent of cell death. Different truncations were generated, and coimmunoprecipitation assays were used to confirm the protein interaction. Ubiquitination assay was performed to detect the ubiquitination levels. Results: We found that the cerebral ischemia-reperfusion induced injury was aggravated in TRIM29 knockout mice after middle cerebral artery occlusion operation as well as the increased neurological deficits score. TRIM29 expression was also found to be up-regulated upon middle cerebral artery occlusion or OGD administration, and loss of TRIM29 promoted the apoptosis and pyroptosis of neurons and microglial cells induced by middle cerebral artery occlusion or OGD, consistent with the enhanced proinflammatory mediators production and activation of NLRC4 (NLR [NOD-like receptor] family CARD [caspase recruitment domain] domain containing protein 4) inflammasome. Furthermore, we observed that TRIM29 interacted with NLRC4 directly and promoted the K48-linked polyubiquitination of NLRC4, lead to the proteasomal degradation of NLRC4. Conclusions: In conclusion, for the first time, we revealed the role of TRIM29 in ischemic stroke and illustrated the direct relationship between TRIM29 and NLRC4.
- 1 May 2023
- Published by Wolters Kluwer Health in Stroke
- Vol. 54 (5) , 1377-1389
TRIM29 (Tripartite Motif Containing 29) Alleviates NLRC4 (NLR Family CARD Domain Containing Protein 4) Inflammasome Related Cerebral Injury via Promoting Proteasomal Degradation of NLRC4 in Ischemic Stroke
Background: Neuroinflammation plays extremely crucial roles in the neurological damage mediated by ischemic stroke. TRIM29 (tripartite motif containing 29) has previously been proposed to contribute to the regulation of innate immunity, however, the effect of TRIM29 on ischemic stroke induced neurodegenerative processes and neuroinflammation still largely unexplored. In the current article, we aimed to investigate the function and the precise mechanisms of TRIM29 in ischemic stroke. Methods: Middle cerebral artery occlusion mice model and oxygen-glucose deprivation cell model were established as in vivo and in vitro models of ischemic stroke. Quantitative real-time polymerase chain reaction (PCR), Western blot, and ELSIA were used to detect the expression levels of TRIM29, cytokines, and marker proteins. Immunofluorescence assay was performed to examine the extent of cell death. Different truncations were generated, and coimmunoprecipitation assays were used to confirm the protein interaction. Ubiquitination assay was performed to detect the ubiquitination levels. Results: We found that the cerebral ischemia-reperfusion induced injury was aggravated in TRIM29 knockout mice after middle cerebral artery occlusion operation as well as the increased neurological deficits score. TRIM29 expression was also found to be up-regulated upon middle cerebral artery occlusion or OGD administration, and loss of TRIM29 promoted the apoptosis and pyroptosis of neurons and microglial cells induced by middle cerebral artery occlusion or OGD, consistent with the enhanced proinflammatory mediators production and activation of NLRC4 (NLR [NOD-like receptor] family CARD [caspase recruitment domain] domain containing protein 4) inflammasome. Furthermore, we observed that TRIM29 interacted with NLRC4 directly and promoted the K48-linked polyubiquitination of NLRC4, lead to the proteasomal degradation of NLRC4. Conclusions: In conclusion, for the first time, we revealed the role of TRIM29 in ischemic stroke and illustrated the direct relationship between TRIM29 and NLRC4.